Immuron Ltd

IMC

Company Profile

  • Business description

    Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

  • Contact

    Chapman Street
    Unit 10, 25-37
    Blackburn North
    MelbourneVIC3130
    AUS

    T: +61 398245254

    https://www.immuron.com.au

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    7

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,624.906.60-0.08%
CAC 407,788.1038.69-0.49%
DAX 4024,038.19188.30-0.78%
Dow JONES (US)42,235.43108.22-0.26%
FTSE 1008,726.0152.04-0.59%
HKSE23,258.31123.68-0.53%
NASDAQ19,219.0719.910.10%
Nikkei 22537,722.401.71-0.00%
NZX 50 Index12,362.26220.07-1.75%
S&P 5005,916.984.56-0.08%
S&P/ASX 2008,396.9010.70-0.13%
SSE Composite Index3,339.930.76-0.02%

Market Movers